Loading clinical trials...
Loading clinical trials...
Real-world Evidence Non-Interventional proSpective Study of kisqaLi (Ribociclib) Effectiveness and safEty in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
Conditions
Interventions
ribociclib
Locations
2
Saudi Arabia
Novartis Investigative Site
Riyadh, Saudi Arabia
Novartis Investigative Site
Riyadh, Saudi Arabia
Start Date
August 27, 2025
Primary Completion Date
November 30, 2028
Completion Date
November 30, 2028
Last Updated
February 4, 2026
Novartis Pharmaceuticals
CONTACT
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions